Psychedelic Medicine Association Announced Globally
September 17, 2020
Ryan Allway September 17th, 2020 Psychedelics Leaders in the field of psychedelic medicine have joined forces to bridge the gap between the medical establishment, patients, and industry leaders by forming the Psychedelic Medicine Association (PMA). As psychedelic medicines progress through clinical trial pathways, and legislation is amended, patients are... Read more
Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets
Uncategorized September 15, 2020
Ryan Allway September 15th, 2020 Psychedelics, Top News, Uncategorized DENVER, Sept. 15, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value. Topics that the... Read more
Pure Extracts: An Experienced Team with an Attractive Model
Uncategorized September 15, 2020
Ryan Allway September 15th, 2020 Psychedelics, Top Story, Uncategorized The cannabis industry has matured into a multi-billion-dollar business over the past few years, but growing interest in psilocybin and functional mushrooms has opened the door to a new horizontal business opportunity. Like cannabis, mushrooms are a natural product with... Read more
Numinus Announces Closing of Oversubscribed $4.6 Million Offering
September 11, 2020
Ryan Allway September 11th, 2020 Psychedelics Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent’s option in its entirety in the form of... Read more
Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin
September 11, 2020
Ryan Allway September 11th, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that, on August 31, 2020, its wholly-owned subsidiary, HAVN... Read more
AWAKN Life Sciences Launches Clinical Research Division
September 11, 2020
Ryan Allway September 11th, 2020 Psychedelics AWAKN Life Sciences Inc (“AWAKN”), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division. AWAKN’s purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business... Read more
Field Trip Psychedelics Inc. Introduces Trip, a Mobile App Designed to Expand Your Mind
September 9, 2020
Ryan Allway September 9th, 2020 Psychedelics Field Trip Psychedelics Inc. (“Field Trip” or the “Company”), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced the launch of its first-ever app, Trip. A first-of-its-kind app and experience, Trip allows people from... Read more
HAVN Life Sciences Announces Completion of Acquisition Transaction
September 4, 2020
VANCOUVER, BC / ACCESSWIRE / September 4, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (the “Company” or “Havn Life”), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research“), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction“). HAVN Research... Read more
Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days
September 3, 2020
DENVER, Colorado, USA, September 3, 2020 — Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine”, “MIG” or the “Company”) is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that were due to be released on September 6, 2020, for... Read more
Numinus Announces Filing of Final Short Form Prospectus for Offering of up to $4,000,000
September 3, 2020
Ryan Allway September 3rd, 2020 Psychedelics, Top News VANCOUVER, BC, Sept. 3, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce it has filed a... Read more
